CN104470509A - 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途 - Google Patents

剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途 Download PDF

Info

Publication number
CN104470509A
CN104470509A CN201380021969.0A CN201380021969A CN104470509A CN 104470509 A CN104470509 A CN 104470509A CN 201380021969 A CN201380021969 A CN 201380021969A CN 104470509 A CN104470509 A CN 104470509A
Authority
CN
China
Prior art keywords
μms
cancer
dexanabinol
carcinoma
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380021969.0A
Other languages
English (en)
Chinese (zh)
Inventor
马尔科姆·菲利普·扬
菲利普·麦基翁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
THERAPEUTICS PLC E
Original Assignee
THERAPEUTICS PLC E
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by THERAPEUTICS PLC E filed Critical THERAPEUTICS PLC E
Publication of CN104470509A publication Critical patent/CN104470509A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N7/00—Ultrasound therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201380021969.0A 2012-04-26 2013-04-26 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途 Pending CN104470509A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1207305.2 2012-04-26
GBGB1207305.2A GB201207305D0 (en) 2012-04-26 2012-04-26 Therapy
PCT/GB2013/000183 WO2013160645A1 (en) 2012-04-26 2013-04-26 Dexanabinol or a derivative thereof for use in the treatment of cancer in dose ranges of 2-30 mg/kg

Publications (1)

Publication Number Publication Date
CN104470509A true CN104470509A (zh) 2015-03-25

Family

ID=46330386

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380021969.0A Pending CN104470509A (zh) 2012-04-26 2013-04-26 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途

Country Status (9)

Country Link
US (1) US20150072020A1 (https=)
EP (1) EP2874615A1 (https=)
JP (1) JP2015514796A (https=)
CN (1) CN104470509A (https=)
AU (1) AU2013254468A1 (https=)
CA (1) CA2868677A1 (https=)
GB (1) GB201207305D0 (https=)
WO (1) WO2013160645A1 (https=)
ZA (1) ZA201408641B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020113877A1 (zh) * 2018-12-04 2020-06-11 天津医科大学总医院 E2f6抑制剂的功能与用途

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107898791A (zh) 2010-06-03 2018-04-13 药品循环有限责任公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
CN104704129A (zh) 2012-07-24 2015-06-10 药品循环公司 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变
US10610512B2 (en) 2014-06-26 2020-04-07 Island Breeze Systems Ca, Llc MDI related products and methods of use
WO2016106381A1 (en) * 2014-12-23 2016-06-30 Pharmacyclics Llc Btk inhibitor combinations and dosing regimen
WO2017068349A1 (en) * 2015-10-23 2017-04-27 E-Therapeutics Plc Cannabinoid for use in immunotherapy
GB201903546D0 (en) * 2019-03-15 2019-05-01 Ldn Pharma Ltd Cancer treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077832A2 (en) * 2002-03-18 2003-09-25 Pharmos Corporation Dexanabinol and dexanabinol analogs regulate inflammation related genes
CN101808636A (zh) * 2007-07-06 2010-08-18 e-生物有限公司 黑色素瘤的治疗
WO2011030106A1 (en) * 2009-09-10 2011-03-17 E-Therapeutics Plc Cancer cell apoptosis

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3249109A (en) 1963-11-01 1966-05-03 Maeth Harry Topical dressing
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4262003A (en) 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4307717A (en) 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
IL80411A (en) 1986-10-24 1991-08-16 Raphael Mechoulam Preparation of dibenzopyranol derivatives and pharmaceutical compositions containing them
IL115245A (en) 1995-09-11 2002-12-01 Yissum Res Dev Co Tumor necrosis factor inhibiting pharmaceuticals
EP1299374B1 (en) 2000-06-22 2006-12-27 Pharmos Corporation Novel non-psychotropic cannabinoids
JP2006509038A (ja) * 2002-12-04 2006-03-16 ファーモス コーポレイション 医薬組成物用の高エナンチオマー純度を有するデキサナビノール
IL153277A0 (en) * 2002-12-04 2003-07-06 Pharmos Corp High enantiomeric purity dexanabinol for pharmaceutical compositions
WO2004105700A2 (en) * 2003-05-28 2004-12-09 Guildford Pharmaceuticals, Inc. Compounds, methods and pharmaceutical compositions for inhibiting parp
WO2006078903A1 (en) * 2005-01-21 2006-07-27 Matthews Richard H Radiosensitizer formulations comprising nitrohistidine derivatives
ES2605815T3 (es) * 2008-07-01 2017-03-16 Ptc Therapeutics, Inc. Moduladores de la expresión de la proteína Bmi-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003077832A2 (en) * 2002-03-18 2003-09-25 Pharmos Corporation Dexanabinol and dexanabinol analogs regulate inflammation related genes
CN101808636A (zh) * 2007-07-06 2010-08-18 e-生物有限公司 黑色素瘤的治疗
WO2011030106A1 (en) * 2009-09-10 2011-03-17 E-Therapeutics Plc Cancer cell apoptosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020113877A1 (zh) * 2018-12-04 2020-06-11 天津医科大学总医院 E2f6抑制剂的功能与用途

Also Published As

Publication number Publication date
ZA201408641B (en) 2016-03-30
WO2013160645A1 (en) 2013-10-31
GB201207305D0 (en) 2012-06-13
JP2015514796A (ja) 2015-05-21
US20150072020A1 (en) 2015-03-12
CA2868677A1 (en) 2013-10-31
AU2013254468A1 (en) 2014-11-27
EP2874615A1 (en) 2015-05-27

Similar Documents

Publication Publication Date Title
ES2904880T3 (es) Terapia combinada con inhibidores de Notch y de PD-1 o PD-L1
CN103635192B (zh) Akt抑制剂化合物和化疗剂的组合以及使用方法
AU2015278765B2 (en) Intermittent dosing of MDM2 inhibitor
CN106470696B (zh) 用于治疗癌症的药物组合
JP2025072587A (ja) 治療組成物、組み合わせ、及び使用方法
CN104470509A (zh) 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途
KR20240014585A (ko) 악성 종양 치료용 제제 및 조성물
TWI762784B (zh) Cdk4/6抑制劑與egfr抑制劑聯合在製備治療腫瘤疾病的藥物中的用途
US20200281923A1 (en) Use of parp inhibitor in treating chemotherapy-resistant ovarian cancer or breast cancer
US20250262214A1 (en) Intermittent dosing regimen for azenosertib in treating cancer
JP2015214579A (ja) 癌細胞アポトーシス
CA2944255C (en) New derivatives of cephalosporin for treating cancer
JP2016520665A (ja) Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ
CN115803629A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法
CN115397415A (zh) 乳腺癌治疗剂
US20230000876A1 (en) Treating cancers with a cyclin-dependent kinase inhibitor
KR20220008870A (ko) 노치-활성화 유방암을 치료하기 위한 비스플루오로알킬-1,4-벤조디아제피논 화합물
WO2020057536A1 (zh) 用于治疗脑肿瘤的喹啉衍生物
CN107137407B (zh) 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途
JP2013527248A (ja) ウォルトマンニンアナログによる癌の処置
TW202146016A (zh) 投予抗癌劑之方法
WO2020239051A1 (zh) Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途
JP2022507686A (ja) 薬学的方法
CN115190800A (zh) 一种brd4抑制剂的用途
HK40087480A (zh) 使用HIF-2α抑制剂和乐伐替尼的组合治疗癌症或VON-HIPPEL LINDAU病的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150325